Hemostemix Inc. is a clinical-stage biotechnology company focused on developing blood-derived stem cell therapies for various medical conditions in Canada. While the recent 9.09% price increase may indicate some investor interest, the company faces significant concerns, including a negative return on assets of -33.2% and a low current ratio of 0.34, suggesting liquidity issues. These financial metrics highlight potential risks in sustaining operations and funding future development. Overall, the company's valuation remains low, reflecting investor caution amid its clinical-stage status and financial challenges.
Loading financial metrics...
Company has $825K in cash but burned $579K last quarter. At this burn rate, only 1.4 quarters of runway remain without additional financing.
Company posted a loss of $-5.2M over the last year, representing Infinity% of revenue.
Debt of $4.9M is 5.9x the company's cash position of $825K.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q2 (June 30, 2025)